Esomeprazole placebo

Esomeprazole placebo refers to the pharmacologically inactive substance used as a control in clinical trials sponsored by Onconic Therapeutics, specifically for the study of erosive gastroesophageal reflux disease (GERD). In these trials, such as the Phase II study comparing the novel potassium-competitive acid blocker (P-CAB) zastaprazan (JP-1366) to esomeprazole, the placebo is utilized in a double-dummy design. This ensures that patients and investigators remain blinded to the treatment assignment by providing a placebo that is physically identical to the active esomeprazole 40mg comparator. The use of this placebo allows for the accurate assessment of the safety and efficacy of the investigational drug relative to the established proton pump inhibitor (PPI) standard of care.

Other names

PlaceboEsomeprazole-matched placeboesomeprazole placebo-Onconic Therapeutics Inc.-erosive gastroesophageal reflux disease